Related Experiment Videos
Management of older adults with hypercholesterolaemia
J T Pacala1, P E McBride, S L Gray
1Department of Family Practice and Community Health, University of Minnesota School of Medicine, Minneapolis.
Insights
Selective screening and tailored treatment for dyslipidaemia in older adults are crucial for preventing coronary heart disease (CHD). Cholesterol subfractions and risk factors guide management, emphasizing nutritional therapy first, followed by cautious pharmacological intervention.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Pharmacology
Background:
- Coronary heart disease (CHD) prevalence increases with age, despite declining total cholesterol's relative risk.
- Dyslipidaemia treatment shows potential for CHD prevention in older adults, especially those with existing CHD or multiple risk factors.
Purpose of the Study:
- To outline selective screening strategies for dyslipidaemia in the elderly.
- To guide therapeutic decisions for managing dyslipidaemia in older populations.
Main Methods:
- Review of cholesterol treatment trial data in older adults.
- Analysis of the role of cholesterol subfractions, including high-density lipoprotein cholesterol (HDL), and triglycerides (TG).
- Consideration of nutritional and pharmacological interventions, including cost-effectiveness.
Main Results:
- Selective screening for dyslipidaemia is recommended for elderly individuals amenable to therapy with existing CHD or multiple risk factors.
- Measuring cholesterol subfractions (HDL) and TG is vital for assessing dyslipidaemia severity.
- Nutritional therapy is the primary approach for high-risk, non-debilitated older adults; pharmacological options require careful consideration due to potential adverse effects and interactions.
Conclusions:
- Dyslipidaemia management in older adults necessitates a personalized approach, considering individual risk factors and health status.
- Cholesterol subfractions are key indicators for assessing dyslipidaemia severity and guiding treatment decisions.
- Pharmacological interventions for dyslipidaemia in the elderly require careful risk-benefit assessment, considering age-related efficacy and safety profiles.
Abstract:
Although the strength of total cholesterol levels as a relative risk factor for coronary heart disease (CHD) declines with age, the prevalence of CHD increases dramatically with age. Data from cholesterol treatment trials, although sparse in older adults, suggest that dyslipidaemia treatment has the potential to prevent CHD. In particular, dyslipidaemia treatment appears to be most beneficial in older adults with a history of CHD or who have several other CHD risk factors. Dyslipidaemia screening should be selective in the elderly, reserved for those whose health status would be amenable to nutritional or pharmacological therapy, and in whom several CHD risk factors or a history of CHD are present. Since high density lipoprotein cholesterol (HDL) levels retain their inverse association CHD in old age, cholesterol subfractions should be measured in persons being screened in order to adequately assess the severity of dyslipidaemia. Treatment decisions should be guided by the patient's dyslipidaemic class, which is determined by the cholesterol subfractions and serum triglycerides (TG). As in younger persons, nutritional therapy remains the first step in dyslipidaemia management in high risk, nondebilitated older adults. An array of cholesterol modifying medications are available which vary widely in treatment effects, adverse effects and cost. Extra care needs to be taken in prescribing these agents in older adults because of greater potential for adverse effects and interactions with other medications. The cost-effectiveness of pharmacological treatment decreases with age and increases with the severity of dyslipidaemia, a history of CHD, or the presence of multiple CHD risk factors. When comparing elderly to middle-aged adults, the relative cost-effectiveness of different cholesterol-lowering medications may be altered due to age-related changes in therapeutic efficacy and adverse effects.